Bruno Sangro

机构：Instituto de Salud Pública de Navarra, Navarre Institute of Health Research, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Clinica Universidad de Navarra, Universidad de Navarra · ORCID：0000-0002-4177-6417

发表论文 801 篇 · 总被引 50800 次 · h-index 97

代表论文

• BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update (2025 · Journal of Hepatology · 被引 147)
• Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma (2025 · Journal of Hepatology · 被引 11)
• 1494P Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the phase III HIMALAYA study (2025 · Annals of Oncology · 被引 4)
• Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis (2025 · Liver Cancer · 被引 3)
• Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma (2026 · Cell Reports Medicine · 被引 1)
• In vitro and in silico assessment of a multi side-hole catheter for transcatheter endovascular treatments on arterial bifurcations (2025 · Results in Engineering · 被引 1)